Where Pharma and Medtech
Pricing & Market Access Leaders Meet

The 8th annual EPP Life Sciences Pricing Forum was the “must” go event for Pricing and Market Access senior executives and innovators, who want to learn and discuss the trends and developments in the pharma and medtech  pricing and profit optimisation area.

2018’s forum was completely re-designed to cover the most up to date pricing and market access real-world insights, trends and real case studies with information not available in any other event.

Our goal was to provide the most interactive and pioneering content forum, deeply detailed, in a setting with your industry peers where you will be able to network, learn and discuss about pricing strategy, payers’ relationships, price policy and innovative pricing tools. The forum offers 3 interactive days with workshops, expert presentations, panel sessions, roundtables discussions, a great evening event and many more networking activities.

Join us at Europe’s most influential pricing forum!                         Watch last year’s (2017) event video

 

Download the forum brochure (use button in top navigation)
today to see the full speaker faculty and programme                                                                                                 

 

Key themes chosen by the industry

 

Ο

Stay ahead of the game :
Examine the latest pricing trends 
and Life Science developments
  • The Pricing Evolution – Hear the latest pricing trends and developments in Life Sciences and how the future is shaping
  • Impact of blockchain technology on contracting
  • Use of Machine Learning technology for price getting
Ο

Empower
payers’ collaboration
  • Hear directly from payers how Life Sciences can engage and work successfully with payers
  • Analysis of the complexity of different payers around the world – understanding the different ways to value a drug and how pricing and market access play a crucial role
  • How to communicate the evidence to price optimization
 Ο
Optimise your strategic pricing to ensure commercial success
(Pharma & MedTech Tracks)
  •  Ensure an effective localization & indirect channel pricing strategy
  • Partnerships between the sales and pricing teams to improve profitability
  • The evolving Biosimilars landscape – key biosimilar trends and dynamics across Europe
  • The present and future for oncology pricing strategies
  • Drive optimal price setting for your portfolio
  • Hear how to create an effective risk sharing agreement and pay by performance model
  • Subscription based pricing models
 Ο
Implement innovative pricing models, contracting & tendering
(Pharma & MedTech Tracks)
  • Innovating value-based contracting models & economic models in Life Sciences
  • Indication based-pricing model – Analysis of the latest Life Science developments and implementations
  • Enhance launch sequence strategies and the timings to optimise global revenue
  • Explore how a successful outcome-based contracting can guaranty business success
  • Tender management excellence: Hear successful value-based & data-based tendering strategies
  • Gross-to net best practices and the value of applying them
  • Early price and early value assessment models
  • Insights on current Managed Entry Agreements
  • Hear how to create an effective risk sharing agreement and pay by performance model
  • Subscription based pricing models
 Ο
Embrace new technology tools & data management
  • How predicted reimbursement analytics can help you to optimise your pricing and profit strategy
  • The evolving data ecosystem: Understand how the industry is embracing Real-World Data to price optimisation
  • Transform your processes and systems to a successful pricing dynamics management
  • Pricing automation: techniques to improve the pricing offering and the incorporation of machine learning to optimize the process

Download the forum brochure today to see the full speaker faculty and programme

If you would like to be part of this amazing forum next year : please contact us: mariana.flores@pricingplatform.eu or  britt.dejager@pricingplatform.eu or just give us call +32(0)473.71.76.69


5 reasons why you should attend the EPP Life Sciences Pricing Forum in 2018 

  1. 120+ senior level executives come together for exclusive keynote presentations, innovative workshops, 2 breakouts on Pharma and MedTech, roundtables discussions and unrivalled networking to engage in high level business discussions that will shape the future of pricing and market acces
  2. The forum agenda was created together with key industry influencers to include the main industry’s challenges and opportunities
  3. 25+ Speakers delivering interactive workshops, roundtables, panel discussions and ground-breaking presentation
  4. Pharma & MedTech Breakouts: Discuss, learn and challenge both strategic and tactical topic
  5. Networking: Face-to-face conversations with top industry experts and your pricing peers during the innovative and interactive forum format – you will meet and do business with the leading industry leaders

Watch last year’s (2017) event video


Who will be attending?

Every year 120+ medtech and pharma attendees gather to discuss and reflect on the latest pricing and market access trends, learn about best business practices and meet world’s best experts in pricing and profit optimisation.

The EPP Life Sciences Pricing Forum brings together leading practitioners and experts to discuss, reflect, network and share. The forum is tailored for key stakeholders such as: Pricing, Reimbursement, Market Access, Commercial, Marketing and Sales Directors and VPs, CEOs and General Managers.

Download the forum brochure (button in top navigation) today to see the full speaker faculty and programme 

ATTENDING WITH 2+ GROUP : contact: mariana.flores@pricingplatform.eu or  britt.dejager@pricingplatform.eu or call +32(0)473.71.76.69.


This is an event you must attend!

  • 1 BUILD RELATIONSHIPS

    With more than 1000 minutes of network opportunity, you have plenty of time to connect with pricing colleagues from all over Europe.

  • 2 DISCUSS

    We stimulate an atmosphere of discussion and interaction, the best way to learn.

  • 3 LEARN FROM THE BEST

    A carefully selected speaking team of top pricing professionals, all active within your industry. No general talk, but only to-the point and useful presentations.

  • 4 REFLECT & PRACTICE

    Reflect on your key priorities and how to make it really happen !  Translate your key learnings into real change.

THE PROGRAMME

Download the forum brochure today to see the full speaker faculty and programme

03 Oct
13.00-15.30
WS 1: Regenerative medicine pricing and market access: readiness for the next pricing revolution Mondher Toumi - Aix Marseille University

- After biologics and targeted therapies, a new class of products called regenerative medicine in US and advance therapeutic medicinal products (ATMP) in Europe is emerging.
- These product have some specificities such as a single administration with life lasting benefit, potential to cure severe and also fatal conditions ; but with a lack of long term consequences and high uncertainty on treatment durability.
- Payers and Industry pricing manager need to be aware of the specificities of those products to ensure proper decision are taken to ensure readiness of these dramatic environment changes.

03 Oct
13.00-15.30
WS 2 : Finding your competitive edge in MedTech: balancing costs and benefits for optimal decision making Luca Morreale and Przemyslaw Kuznicki - HighPoint Solutions

-In today’s competitive environment within Life Sciences and especially MedTech, which is subject to constant pricing pressure and more powerful purchasing authorities, defining your commercial strategy is becoming more and more challenging.
-Navigating with more insights will help you find the right balance between costs and benefits to optimize your decision making process.
-In our workshop, HighPoint will conduct a simulation forcing you to make difficult choices as a team in a competitive environment as well as stimulating constructive thinking around how to structure and prioritize decisions, information needs, and resources.

03 Oct
16.00-18.30
WS 3: Best Practices for Shaping & Winning Tenders Alan Crowther - Alliance Life Sciences

-This intense, 2.5-hr workshop will present best practices for shaping and winning tenders. It will operationalize a review of all major pricing tools, analytics techniques and tender scoring based on machine learning technologies.
- Experience through hands-on exercises with a broad set of analytical pricing techniques and takeaway kit of KPIs and visualisations for understanding tender pricing performance
- Advanced tender scoring knowledge : how it can be done and how machine learning can impact it

03 Oct
16.00-18.30
WS 4 : Generate Real-World Evidence through partnerships with healthcare providers. Paolo Correale - Tefen Management Consulting

- Learn how to design partnership ideas and appropriately engage healthcare stakeholders
- Review some examples of successful partnerships
- Discuss implications for value-based pricing and access Also applicable to pharma

October 4th 2018
08:00 Registration and networking coffee Hosts - EPP
08.40 Welcome Pol Vanaerde, President - - EPP
08.50 Chairman's opening remarks Mukarram Bhaiji - Director Global Pricing Strategy - Smith & Nephew

* Speed Networking Session – Meet all the attendees and exchange business cards

Session 1 · Stay ahead of the game – Examine the latest pricing trends and Life Science developments --------------------------------------- - ---------------------------------------
09.00 Hear how to create an effective risk sharing agreement and pay for performance model Alla Uhrlandt - Director Strategic Pricing EMEA  - Janssen Pharmaceutical Companies of Johnson & Johnson
  • Risk sharing & performance-based agreements in Pharmaceutical and Medical Devices – taxonomy & experiences so far, payers’ and industry’ expectations in the future
  • Strategic, Financial and Legal considerations when implementing risk sharing agreements, both financial- & performance-based
  • Outcome-/ performance-based models: the key challenges, barriers and solutions for implementation
  • Why connecting incentives and payment to outcomes is well-suited for the future healthcare system and delivers value for patients, payers and industry a like

 

09.30 Square logo Sanofi International reference pricing (IRP) Management in Life Sciences Halima Benghabrit - Global Pricing Head of Established Products - Sanofi

Health Authorities around the world strive to contain costs of medicines, International Reference Pricing (IRP) is one of the key mechanisms to keep drug costs down. The WHO Collaborating Centre for Pricing and Reimbursement Policies defines IRP as: “The practice of using the price(s) of a medicine in one or several countries in order to derive a benchmark or reference price for the purposes of setting or negotiating the price of the product in a given country”. As a result, drug price in one country will influence the prices in the other countries.

* Analysis how IRP is one of the most complex constraints affecting the pharma industry and how it makes it difficult to both optimizing launch strategy and managing price erosion till after LoE
* Aim and mechanisms and management through the whole products LCM

10.00 Samoan Circle Session – get your point heard! Transparency of pricing across markets for Medtech and Pharma Multiple active speakers -

Active participants sit surrounded by listeners. Anyone who wants to talk may step forward to enter the inner circle. You can enter the inner circle at any time, including to stop somebody else from talking. Participants must retire when prompted.

Transparency of pricing across markets
. Learn how to map your buying groups and achieve price transparency across markets
. Strategic pricing: How do we provide a certain price to a certain client? And avoid the risk of losing value across markets
. Communication excellence: How are we addressing the communication gap? – Hear different approaches on how companies are improving their strategy to customers

Moderation: Mukarram Bhaiji – Director, Global Pricing Strategy – Smith & Nephew
Halima Benghabrit – Global Pricing Head of Established Products – Sanofi
Slobodan Farago – Commercial Excellence Manager MDS Europe – BD
Alla Uhrlandt – Director Strategic Pricing EMEA – Janssen Pharmaceutical Companies of Johnson & Johnson
Gianclaudio Floria
– Senior Director, Head of Global Pricing and Market Access – Fresenius Kabi SwissBioSim

 

10.40 Coffee Break and Networking -
11.10 Zooming out: Improving Commercial Performance Through Strategic Pricing Alan Crowther, President of Global Markets - Alliance Life Sciences

Life Science is being subject to tsunami-size changes in the space of pricing. Decisions on pricing aren’t country-independent anymore, due to the global extension of IRP (International Reference Pricing), parallel trade and other cross-country initiatives. Ex-factory prices are becoming less and less relevant, with other models moving from pilot stage to wider implementation. Finally, the already strong public pressure for pricing scrutiny is making value-based pricing a mandatory focus area for senior executives. In this context, Life Sciences’ ability to evolve core business processes by integrating strategic pricing components and capabilities, is critical for commercial performance:

  • What are major trends that will disrupt current pricing models
  • Examine how to integrate strategic pricing in core business processes, from Product Development, to Long Term Strategic Planning or annual country Operating Plans
  • How to define a global governance model that will adapt to changes in pricing models
  • Define how to leverage business technology systems to drive performance
11.40 Emerging markets – Opportunities and challenges on Market Access and Pricing in Medtech and Pharma Libor Minichbauer - Head of Pricing & Payer Programs - Novartis Oncology Region EGM

* Understand how these markets work, their potential and price dynamic
* Affordability programs in emerging markets

12.10-13.10 Networking lunch Be part of our Birds of a Feather (BOF) Activity ! -

Make the most of your networking time during lunch, join a group of people with a common interest or area of expertise to informally work together, discuss and network. interest or area of expertise to informally work together, discuss and network.

Session 2 · Optimise your strategic pricing to ensure commercial success --------------------------------------- - ---------------------------------------
13.10 Icon EPP Java Junction Industry Tracks Break-out - sessions

 

PHARMA TRACK
Moderator: Ruven Remo Eul
Director, Life Sciences
HighPoint Solutions
MEDTECH TRACK
Moderator: Gary Watson
Executive Vice President
Alliance Life Sciences
13.10 Using real world evidence for making optimal pricing decision

  • Explore how RWE will ensure price transparency, market access and commercial success for your technology
  • Find out how in some countries substantial co-payments for patients exist
  • The effect oon medical demand and implications on pricing

Jörg Mahlich, Head of Health Economics and Outcomes Research, Janssen pharmaceutical

How to eat the service elephant ?

Deloitte research has indicated procurement in the health care sector is clearly moving away from traditional lowest price procurement strategies and product buying. Instead, it is moving its focus towards quality, services and solutions.

However, how to eat that ‘service’ elephant?  This session will showcase participants the different elements of an end-to-end service-offering: from picking the right services to win the competitive battle, up to defining the go-to-market strategy and applying the right pricing frameworks.

  • The importance of services and solutions and their impact in terms of go-to-market strategy
  • How to best price different type of services (economic value estimate, conjoint, cost-plus)
  • The potential impact to shift from product to service and solutions might have on a company’s end-to-end processes

Marc Abels, Partner, Monitor Deloitte Belgium
Ben Desmet, Senior Manager, Monitor Deloitte Belgium

13.40  The evolving Biosimilars landscape – key biosimilar trends and dynamics

  • Panorama of the multiple biosimilar products entering the market –  How the industry is shaping and key future considerations
  • Analysis of key challenges about pricing biosimilars – how to convince payers and policy makers about sustainable pricing mechanism
  • Hear a successful real case study on gainsharing to increase access to biosimilar medicines

Maarten Van Baelen, Market Access Director – Medicines for Europe

How to mitigate Price Erosion in a mature MedTech market

  • Understand the roots of Price Erosion
    . Market Induced
    . Competition Induced
    . Process Induced
  • Measure and Monitor Price Erosion
    . Challenges
    . Impact of methods
  • Mitigate Price Erosion – Limitations and Opportunities
    . Price Governance
    . Market and Tender Shaping –
    . Procurement Processes
    Business Models and Pricing Tactics
  • Trade-offs between Long-Term and Short-Term Objectives
    . Understand Strategic Goals versus          Operational Goals
    . Pricing and Organizational Alignment

Slobodan Farago – Commercial Excellence Manager – MDS Europe

14.10 Roundtables Discussion 

  • How to demonstrate value of your drug and manage different stakeholders
  • Using real world evidence for making optimal pricing decisions
  • The evolving Biosimilars landscape – key biosimilar trends and dynamics across Europe
Roundtables Discussion 

  • How to migate Price Erosion in a mature Medtech market ?
  • The importance of services and solutions and their impact in terms of go-to-market strategies
  • Partnerships between sales and pricing teams to improve profitability
15.10 Coffee and Networking Break -
15.25 PRI Assessment Results -

The PRI is addressed to Pricing Leaders at Life Sciences companies to assess their organisation’s ability, to optimise its pricing performance in today’s competitive business environment, as well as to swiftly adapt to rapidly changing market dynamics.

The index is endorsed by EPP and has been developed by two companies with special focus on the Life Sciences industry, Cube RM (a company of BEL, creator of the iPAT), a software vendor specializing in Pricing Management & Optimization solutions and TEFEN, an international Management Consulting company with significant experience in Pricing and Market Access.

It covers the full spectrum of pricing excellence including Portfolio Price Setting & Execution and the use of advanced Data Analytics & Pricing Software giving detailed readiness scores per focus area.

15.40 Partnerships between the sales and pricing teams to improve profitability Reginald Lassagne - Director, Global Pricing - LivaNova
  • Getting the sales team to understand the importance of pricing
  • Guiding sales to set the right price for certain customers
  • Managing price expectation within all the internal teams

 

Session 3 – Embrace new technology tools & data management --------------------------------------- - ---------------------------------------
16.10 Photo Life Sciences - Daniel Cho Pricing Management & Analytics Excellence Daniel Cho - Director Marketing, Global Pricing & Competitive Portfolio Analytics - PhilipsHealthcare

* Find out how to use analytics to help improve profitability with concrete examples
* Market deep dive and margin recovery – Hear two very powerful case studies from India and Germany
* How to apply Competitive Intelligence to gain pricing advantages

16.40 Interactive Panel Session The evolving data ecosystem: Understand how industry and payers should be embracing Real-World Evidence to price optimisation -

* Learn how to create the value beyond the pill by enabling patient-centred healthcare
* See how incorporating Real-World Evidence and data analysis in early pricing development can provide commercialisation success and offer transparency
* Understanding how data and pricing analytics can influence key pricing decision making

Panel :
Moderator: Ruven Remo Eul –
Director, Life Sciences – HighPoint Solutions
Maarten Van Baelen
, Market Access Director – Medicines for Europe
Jörg Mahlich, Head of Health Economics and Outcomes Research, Janssen pharmaceutical
Daniel Cho – Director Marketing, Global Pricing & Competitive Portfolio Analytics – Philips Healthcare
Gabriel Benthall – Global Pricing Manager – UCB

 

17.20 Logo Smith & Nephew Reflection and evening event news Mukarram Bhaiji - Director, Global Pricing Strategy - Smith & Nephew
Evening networking event ! -

A tour and a diner with a view at the Glion Institute of Higher Education.

More info on our blog: https://www.pricingevents.eu/evening-activity-confirmed/

October 5th 2018
8:30 Enjoy a good cup of coffee -
08.50 Photo Daniel Cho Chairman's opening remarks Daniel Cho - Director Marketing, Global Pricing & Competitive Portfolio Analytics - Philips Healthcare
Session 4 · Implement innovative pricing models, contracting and value-based tendering --------------------------------------- - ---------------------------------------
09.00 Insights and Outlook for the Biosimilars Procurement in Europe Ruven Remo Eul, Director, Life Sciences - and Gianclaudio Floria, Senior Director, Head of Global Pricing and Market Access, Fresenius Kabi SwissBioSim - HighPoint Solutions

The tendering landscape is evolving, especially with more and more upcoming biosimilar entries. Fresenius is one of the players entering the biosimilar market and their expert, together with HighPoint’s PCMA Europe Lead, will cover some key features of the environment from local specificities to an overall global trend. Gianclaudio Floria & Ruven Remo Eul will focus on some strategies to increase efficiencies under those peculiar market conditions, showcase potential analogies and uses cases across all segments of the Life Science industry and provide an outlook of future market trends.

Insights are shared by ;

Ruven Remo Eul – Director, Life Sciences, HighPoint Solutions – and ;
Gianclaudio Floria, Senior Director, Head of Global Pricing and Market Access, Fresenius Kabi SwissBioSim

09.30 Early price and early value assessment models Scott Murrie, PhD - General Manager, Global Pricing and Gulen Desteli, Global Pricing Manager - GE Healthcare

* Find out how developing an early price and early value assessment strategy creates a comprehensive value communications strateg
* Analysis of the tools used and the results

10.00 Tender management & evaluation using CPQ software and Machine Learning George Boretos, CMO - Cube RM

* The benefits of a centralized system for tender information, evaluation, and management
* Learn how you can access information about past & upcoming tenders in order to better understand your market
* Use sophisticated CPQ software to prepare competitive tender responses, accurately and on time
* Use machine learning to evaluate the performance of tender proposals based on tender criteria and competitive information

10.30 Coffee and Networking Break -
11.00 Icon EPP Java Junction Industry Tracks Break-out - sessions

 

PHARMA TRACK

Moderator: Ruven Remo Eul
Director, Life Sciences
HighPoint Solutions

MEDTECH TRACK

Moderator: Gary Watson
Executive Vice President
Alliance Life Sciences

11.00 Novel-Novel combination regimen pricing : is pharma ready ?

 

  • A look at the reimbursement and pricing environment and challenges for combination therapy pricing
  • Addressing the information gap : infrastructure needed for combination pricing
  • Case studies on pricing of Novel-Novel combination therapies

Dr. Marco Rauland – VP MAP GM&E and training Academy – Merck KgaA

Pricing and profitability management strategies – Optimize your Gross-to-Net process

  • Gross-to net best practices and the value of applying them
  • Rebates & Discounts Management: Understanding where you are, what you need to improve and how to get the whole company involved
  • Explore the key elements to develop a solid commercial strategy by improving your GTN approach
  • What changes you need to implement within your organisation to enhance GTN?

Mukarram Bhaiji – Director, Global Pricing Strategy – Smith & Nephew

11.30 Managed Entry Agreements (MEA) & special agreements insights

  • Review of a win win MEAs strategy and the steps to implement it
  • The use of Managed Entry Agreements to achieve sustainable pricing – Hear a real case study, and the pros and Cons
  • Analysis of Outcome or Financial based Managed Entry Agreements

Fabrizio Gianfrate – Professor of Health Economics – University of Ferrara, Luiss Business School Rome, Italy

Higher growth and profitability with a smart CPQ software

  • Understand how to set certain pricing rules in line with global and local strategies
  • Automatic escalations and approvals: faster, simpler and no human error
  • Explore how to facilitate upselling and cross-selling opportunities

Özkan Tezgin – Global FP&A Manager – Leica Microsystems

12.00 Interactive Campfire Storytelling Session

Be ready to share your own pricing experiences with others!

The facilitator will introduce current pricing topics and encourage a discussion trying to reveal common issues and solutions.

Interactive Campfire Storytelling Session

Be ready to share your own pricing experiences with others!

The facilitator will introduce current pricing topics and encourage a discussion trying to reveal common issues and solutions.

 

12.30-13.30 Networking lunch Be part of our Birds of a Feather (BOF) Activity ! -

Make the most of your networking time during lunch, join a group of people with a common interest or area of expertise to informally work together, discuss and network. interest or area of expertise to informally work together, discuss and network. 

Session 5 · Empower payers' collaboration --------------------------------------- - ---------------------------------------
13.30 Market Access in a 2018 NHS/NICE - Challenges and Opportunities Diar Fattah - Associate Director of Medicines Optimisation - NHS

* Analysis of the NHS/NICE Changing landscape
* Find out the impact of real-world evidence
* High cost/rare disease market access impact
* Explore the outcomes-based contracting opportunities

14.00 Innovating value-based pricing models & economic models in Life Sciences Vinciane Knappenberg - Coordinatrice procedures - National Institute for Health and Disability Insurance (RIZIV INAMI) - National Institute for Health and Disability Insurance (RIZIV INAMI)

* Risk sharing agreements & pay by performance schemes overview
* Hear real examples of these models in Europe
* The BeNeLuxA Initiative: vision, aims and results ; How can the Life Sciences industry and the government can work more effectively together

14.30 Payers’ Interactive Q&A Multiple -

Hear directly from payers their key objectives and how the industry can work successfully with them

* Understanding what is important to payers and how the industry can participate to meet payers’ aims
* What payers expect from the Life Sciences industry and what are the new rules to payers’ collaboration
* Payers Alliances: Hear the latest payers’ collaboration & common technology assessment between countries
* Analysis of the main challenges and opportunities for the Life Sciences industry and what does it mean for Pricing

Moderator: Libor Minichbauer – Head of Pricing & Payer Programs – Novartis Oncology Region EGM  :
Panel :
Diar Fattah
– Associate Director of Medicines Optimisation – NHS
Vinciane Knappenberg – Coordinatrice procedures – National Institute for Health and Disability Insurance (RIZIV INAMI)
Fabrizio Gianfrate
 – Professor of Health Economics – University of Ferrara, Luiss Business School Rome, Italy

Closing Inspirational Conference ------------------------------------------- - -------------------------------------------
15.00 Life Sciences’ leadership: analyse how market access & pricing are shaping the future of our industry and how to build a team of leaders Adam Plich - Vice President, Pricing & Market Access Europe - Teva Specialty Medicines, Netherlands - Teva Specialty Medicines
  • Learn how to build a strong leadership team by understanding the qualities required to take your team forward and to overcome future hurdles the industry is facing
  • A complete guide on how to lead our market access and pricing teams
  • Discover which new qualities are required for a high-performance leadership team and understand how the role of pricing and market access need to evolve
15.30 Photo Daniel Cho Final reflections and closing Daniel Cho - Director Marketing, Global Pricing & Competitive Portfolio Analytics - Philips Healthcare

Contact Forum Producer

Mariana Flores

PRE FORUM WORKSHOPS

Interested in delivering a Workshop ?

This can be your space to tell the industry about your innovative solutions and products.
Contact Mariana Flores : e: mariana.flores@pricingplatform.eu -/ m : +44 7792 905 223

WS 1: Regenerative medicine pricing and market access: readiness for the next pricing revolution

PHARMA

03Oct13.00-15.30

  • - After biologics and targeted therapies, a new class of products called regenerative medicine in US and advance therapeutic medicinal products (ATMP) in Europe is emerging.
  • - These product have some specificities such as a single administration with life lasting benefit, potential to cure severe and also fatal conditions ; but with a lack of long term consequences and high uncertainty on treatment durability.
  • - Payers and Industry pricing manager need to be aware of the specificities of those products to ensure proper decision are taken to ensure readiness of these dramatic environment changes.

Mondher Toumi (France) Aix Marseille University

WS 2 : Finding your competitive edge in MedTech: balancing costs and benefits for optimal decision making

MEDTECH

03Oct13.00-15.30

  • -In today’s competitive environment within Life Sciences and especially MedTech, which is subject to constant pricing pressure and more powerful purchasing authorities, defining your commercial strategy is becoming more and more challenging.
  • -Navigating with more insights will help you find the right balance between costs and benefits to optimize your decision making process.
  • -In our workshop, HighPoint will conduct a simulation forcing you to make difficult choices as a team in a competitive environment as well as stimulating constructive thinking around how to structure and prioritize decisions, information needs, and resources.

Luca Morreale and Przemyslaw Kuznicki () HighPoint Solutions

WS 3: Best Practices for Shaping & Winning Tenders

PHARMA

03Oct16.00-18.30

  • -This intense, 2.5-hr workshop will present best practices for shaping and winning tenders. It will operationalize a review of all major pricing tools, analytics techniques and tender scoring based on machine learning technologies.
  • - Experience through hands-on exercises with a broad set of analytical pricing techniques and takeaway kit of KPIs and visualisations for understanding tender pricing performance
  • - Advanced tender scoring knowledge : how it can be done and how machine learning can impact it

Alan Crowther (US) Alliance Life Sciences

WS 4 : Generate Real-World Evidence through partnerships with healthcare providers.

MEDTECH

03Oct16.00-18.30

  • - Learn how to design partnership ideas and appropriately engage healthcare stakeholders
  • - Review some examples of successful partnerships
  • - Discuss implications for value-based pricing and access Also applicable to pharma

Paolo Correale (Italy) Tefen Management Consulting

SPEAKERS

We are proud to announce already a great line-up of experienced speakers for 2018 !!

If you would like to join the speaker faculty, please contact Mariana Flores: mariana.flores@pricingplatform.eu

Gianclaudio Floria

Senior Director, Head of Global Pricing and Market Access

Fresenius Kabi SwissBioSim

Currently leading Pricing and Market Access for Fresenius Kabi Biosimilars Business Unit, Gianclaudio Floria spent the last 15 years of his career in fast growing companies like Gilead Sciences and Amgen in different roles at country, regional and global level. He started his career in Finance and M&A, and moved on to SFE, Market Research, Business Analytics, and – for the last 10 – years Pricing and Market Access.

Alla Uhrlandt

Director Strategic Pricing EMEA

Janssen Pharmaceutical Companies of Johnson & Johnson

Alla is responsible for innovative pricing & access models, regional pricing infrastructure, capabilities and processes across the entire Janssen’s portfolio in the region. Throughout the 16 years of her career, she has broad experience in Pricing, Commercial Excellence, Sales and Technical Marketing in Europe and the USA. With extensive experience in value based pricing & innovative contracting, she has a long track record of developing and implementing commercialization strategy across the Pharmaceutical and Medical Device industry.

Scott Murrie

General Manager, Global Pricing

GE Healthcare

Scott is responsible for the strategic pricing of GE Healthcare’s portfolio and has over 20 years of experience in pricing.  He joined GE Healthcare in 2006 and held leadership positions in Market Access and Global Pricing.  Prior to GE, Scott served in several pricing and product management roles in the telecommunications industry.  Scott holds a PhD in Economics from Oklahoma State University and a BBA in Economics from The University of Oklahoma.  In addition, Scott completed the Oxford Strategic Leadership Program at the Saïd Business School, University of Oxford.

Alan Crowther

President of Global Markets

Alliance Life Sciences

Alan Crowther is President of Global Markets of Alliance Life Sciences, responsible for overseeing the Global Pricing solutions for Alliance. He brings 20 years of leadership, consulting and technology experience with him to the position. Alan has previously held roles as CEO at Alliance; founder of Adjility Health, a firm focused on life sciences analytical software; Vice President at Capgemini; Co-founder and Officer at Adjoined Consulting, where he ran the Life Sciences practice and was part of the leadership of the venture-backed company and helped drive it to a successful $200MM+ exit. Prior to Adjoined, Mr. Crowther was head of services for a small software company that exited to BEA Systems; and was a manager at Andersen Consulting (Accenture) before that. He is a graduate of Princeton University.

 

Slobodan Farago

Commercial Excellence Manager MDS Europe

BD

20 years plus of business and team leadership experience in life sciences (Life Sciences/Pharmaceuticals/Diagnostics/MedTech/Biotech). Well-proven in strategic roles (HQ) with leading industry players and consulting agencies. Value and solution driven mindset. Education background in biological sciences, management and business administration, and pricing. Strong expertise in Commercial Excellence, Sales Force Effectiveness, Business Analytics, Strategic Pricing, Marketing. People management and team leadership routine.

Fabrizio Gianfrate

Professor of Health Economics

University of Ferrara, Luiss Business School Rome, Italy

Phd and Masters in Health Economics (Rome, Stockholm, York). Master in Economic Journalism.

Full Professor of Health Economics, Market Access Consultant, Columnist. Ex-payer as AIFA member (pricing and reimbursement committee), Regional HTA Committees member (several Regions), Director at Ministry of Health (appointed), General Manager and Vice President of GSK Foundation Italy and of Angelini Foundation, several director roles in pharmaceutical industries, secondments in UK and US.

Past: Director of several magazines on healthcare and pharma, formers member of Farmindustria, Assobiotech, CENSIS, EFPIA, Federfarma.
Actual: Board Member of Italian Society of Pharmacoeconomics and Ethicals and Italian society of Healthcare studies).
Author of more than 700 articles and 7 books.

Halima Benghabrit

Global Pricing Head of Established Products

Sanofi

With more than 20 years’ experience in the pharma industry, Halima worked for several European and US companies. She has an extensive experience in marketing, mainly in cardio-vascular, CHC and diabetes areas at country and global level.

She moved 7 years ago to a global market access role before heading market access for emerging markets.

Currently Halima is leading global pricing management for established products. Her team is also in charge of implementing a new global price management tool deployed WW for the whole Sanofi portfolio as well as developing pricing analytics to optimize pricing execution and visibility.

 

 

Photo Daniel Cho

Daniel Cho

Director Marketing, Global Pricing & Competitive Portfolio Analytics

Philips Healthcare

Daniel is the head of a Global Pricing team of 10 which spans in USAndover and Germany Boeblingen, serving the business need forusing pricing as a tool to optimize margin and profitability for a 2.7BEuro business with Philips Healthcare. Daniel and his team built anextensive BI platform based on the Qlikview platform and provide1500+ users daily access to actionable intelligence from CRM (SF.com), OIT, Sales, Margin, Pricing (From SOFON Quotation system+ SAP) and other business data such as Installed Base. Daniel andteam have proven records of reversing the price erosion for all business,helping to improve market business margins within one-year cycle, aswell as improving qualified funnels for high margin business within aquarter. Daniel also had global experience in Product Management,Market Intelligence, New Product Introduction, as well as SalesDevelopment for Asia Pacific and Sales & Marketing experiencefor Asia Pacific. Daniel was also a trained Management Consultantfrom PriceWaterhouse in Sydney. He is now located in BoeblingenGermany for the past 14 years.

Maarten Van Baelen

Market Access Director

Medicines for Europe

The goal of « Medicines for Europe » (formerly EGA) is to improve health by ensuring better access to treatment for patients in Europe and beyond.  As Market Access Director, the objective of Maarten’s team is to shape in the EU a dynamic and sustainable market situation that enables fast and fair pricing and reimbursement for generic, biosimilar and value-added medicines.

Maarten joined « Medicines for Europe » in 2011 as Medical Affairs Manager with responsibilities in the areas of fighting Falsified Medicines and Pharmacovigilance. In his life before the association, he worked in the pharmaceutical industry providing pharmacovigilance consultancy and in the medical device industry liaising with Key Opinion Leaders. He combined these roles while working weekends in a community pharmacy.

Maarten is a pharmacist by education and holds an MBA from “Solvay Brussels School of Economics and Management” and “École des Ponts Paris Business School”.

George Boretos

CMO

Cube RM

George is the CMO of Cube RM, a vendor of Revenue Management & Optimization solutions with specialization in CPQ and Tender Management software. He has more than twenty years of professional experience in managerial positions in product marketing, pricing, corporate strategy, and sales. He is also a seasoned data scientist, specialized in price optimization models, with numerous successful business forecasts and scientific publications to his name in prestigious scientific journals and publishers, such as Elsevier and Foresight. He is a member of the International Institute of Forecasters

Gulen Desteli

Global Pricing Manager

GE Healthcare

Gulen Desteli works as a Global Pricing Manager at GE Healthcare and leads global pricing initiatives to drive profitability in complex markets and institutionalize value based pricing. Desteli is a seasoned pricing professional with 12 years of strategic pricing experience in Healthcare, FMCG, Telecom and Software industries. She holds an MBA from the University of Virginia, Darden School of Business and an undergraduate degree in Economics from Bogaziçi University.

Özkan Tezgin

Global FP&A Manager

Leica Microsystems

Özkan is a professional for over 15 years with the experience spanning across Revenue Management, Pricing, Treasury, Controlling, and Commercial Finance. Having started at E&Y in advisory services, till today, he took both global and European responsibilities at several international companies including General Motors.

In his current role, Özkan drives growth and profitability results by identifying and analyzing revenue and optimization potentials in Leica Microsystems, which is one of the world leaders in microscopes and scientific instruments.

Diar Fattah

Associate Director of Medicines Optimisation

NHS 

A pharmacist and health economist, Diar leads on medicines use and optimisation, prescribing and the provision of pharmaceutical services within the Dartford, Gravesham & Swanley CCG. In addition, he sits on the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee.  His work has been focused on combatting inappropriate polypharmacy with the use of healthcare data analytics.

Reginald Lassagne

Director, Global Pricing

LivaNova

Experienced manager with 14 years of expertise in international and cross-functional environments dedicated to value improvement with regular exposure to senior management and concrete track record in:
– Pricing management: Strategy, Business Modelling, Reporting, Research
– Entrepreneurial Spirit: starting new projects, like Pricing function, from scratch, full Governance set-up
– Tender management: Pretender Strategy, business modelling, coaching, Governance set-up
– Commercial strategy and negotiation B2C, B2B and B2G
– Purchasing management and cost reduction strategy
– Change management: several implementations of ERPs: SAP, BW and new structures

Libor Minichbauer

Head of Pricing & Payer Pro

Novartis Oncology Region EGM

Libor Minichbauer is heading pricing for Novartis Oncology Emerging Growth Markets unit. In his current role he is responsible for pricing and innovative pricing models in 80+ countries in Asia, Middle East, Africa and CIS. Libor has worked in the industry for the last 10 years, held various roles in development, health economics, and pricing. Prior to joining pharma, he has spent several years in consulting, and IT and finance industries. Libor obtained his MBA from DePaul University in Chicago. He also holds a Masters in International Trade and Diplomacy from the University of Economics in Prague and Masters in Pharmacoeconomics from Pompeu Fabra University in Barcelona.

 

Ruven Remo Eul

Director, Life Sciences

HighPoint Solutions

Ruven is a Director within the European Life Sciences team based out of Zug, Switzerland responsible for project oversight and delivery, resource management and solution development in the areas of Pricing, Contracting and Tendering. Ruven brings a background of industry experiences in large pharma from companies such as Pfizer and BMS where he worked in Commercial roles with a large focus on leading cross functional Tendering teams for Pfizer in Germany. While at HighPoint Solutions, Ruven has worked with emerging, mid-tier and large pharma on various Tendering and Contracting programs from policy and process assessments, outsourcing of business functions, software vendor evaluations and implementation of global programs. Additionally, Ruven has conducted the industry’s first Benchmarking Study on Tendering issuing 4 reports presenting the benchmarking results and developed HighPoint’s Tender Data Service THOR focusing on supporting the awareness & planning phase of Tendering while building Competitive and Pricing Intelligence. In parallel, Ruven has also worked deeply in global commercial effectiveness programs.

Jörg Mahlich

Head of Health Economics and Outcomes Research

Janssen pharmaceutical

Jörg Mahlich is head of Health Economics and Outcomes Research at Janssen pharmaceutical companies of Johnson and Johnson in Germany. In addition, he is lecturer of Health Economics at the Economics Department of the University of Vienna and research affiliate at the Düsseldorf Institute for Competition Economics (DICE) of the University of Düsseldorf, Germany. Previous to that he hold different positions in industry and consulting in Austria, Germany, and Japan. He is interested in global pharmaceutical economics and policy. Jörg graduated in economics from the University of Kiel, Germany and holds a doctoral degree in economics from the University of Vienna, Austria.

Mukarram Bhaiji

Director, Global Pricing Strategy

Smith & Nephew

Responsible for designing pricing strategy, policies and governance for Smith & Nephew globally.

Marc Abels

Partner

Monitor Deloitte Belgium

Marc has 17 years of experience in Go to market strategies and a deep expertise in pricing.  He leads the Strategy department (80 consultants) for Monitor Deloitte Belgium. He is one of the ‘pricing’ experts within Deloitte Europe and is a regular speaker on various pricing conferences (e.g. Professional Pricing Society and European Pricing Platform). His main industry focus is on Lifesciences (Pharma, MedTech) but he also has experiences in Manufacturing and Services. Main skills: – Optimization of pricing across product portfolio and channels (incl. resolution of channel conflicts) – Development and commercialization of new offerings (products & services)  – Commercial Excellence and Digital Transformation Programs – Transformations from ‘product’ selling towards ‘solution’ selling and being more customer centric.

Dr. Marco Rauland

Vice President MAP GM&E and Training Academy

Merck KGaA

Marco Rauland has more than 20 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck Marco was Vice President Europe of GfK’s Market Access practice. Before that Marco was the global head of the pricing, access and reimbursement practice of Genactis and Senior director of the pricing and reimbursement business unit at TNS Healthcare (now Kantar Group).

Marco is an expert in global pricing, listing and reimbursement strategy and has extensive experience in implementing pricing, access and reimbursement solutions at all stages of the product life cycle, from early product development to post-launch pricing strategies. He has developed the pricing, access and reimbursement strategy for product launches across numerous therapy areas and has in-depth knowledge of international country pricing & reimbursement systems. Marco studied Biochemistry and Pharmacology at the University of Cologne and holds a PhD in Natural Science.

Gabriel Benthall

Global Pricing Manager

UCB

Gabriel’s primary focus within the Global Pricing team is to facilitate UCB’s operational pricing governance so that pricing & patient access excellence is maintained across UCB’s entire branded portfolio. He is primarily responsible for managing, challenging and synthesising affiliate pricing business cases into long term forecasts for global review. In addition, he aids the effective development and implementation of global strategy by acting as a bridge between Global and Local.

Gabriel started his career as a scientist researching on various areas, including antibiotic resistance and CAR T cells, in both academia and industry. He graduated in Medical Sciences at University of Exeter Medical School (UK) and his Master’s in Drug Design at University College of London (UK).

Adam Plich

Vice President, Pricing & Market Access Europe

Teva Specialty Medicines, Netherlands

Adam Plich is a seasoned global executive with over 10 years of broad-based high-profile success throughout healthcare, growing sales and expanding margins with multi-million dollar impacts. He drives market access, product pricing and sales, along with operational strategy and innovation. Mr Plich has an unmatched reputation for architecting and delivering flawless product launch strategies, with over 10 launches only in the last 5 years. Mr Plich is known for negotiating complex deals, successfully engaging government agencies and insurers, and repeatedly getting favourable pricing results while advancing patient access. He enjoys developing high-performance cultures and transforming organisations. Mr Plich is a recognised authority in pharma, frequent speaker, industry representative and a university lecturer. He is a pharmacist by training with post-graduate degree in strategic marketing.

 

Gary Watson

Executive Vice President

Alliance Life Sciences

Gary Watson is a VP at Alliance Life Sciences Global Pricing practice. Gary oversees PriceRight, an enterprise Price Governance software.  Gary’s background is in management consulting. Earlier in his career, Gary led BearingPoint’s IT Transformation Solutions practice, focused on delivering innovative IT Management strategies, practices and technologies to help clients dynamically balance and manage IT investments, resources and quality with multiple business objectives.

Vinciane Knappenberg

Reimbursement Procedures Coordinator

National Institute for Health and Disability Insurance (RIZIV INAMI)

Vinciane is a pharmacist since 2000. Between 2000 and 2006 worked in pharmacies in Brussels and in Vilvoorde. Since 2006, is employed by the National Institute for Health & Disability Insurance (NIHDI), first as a file manager for the Commission for Reimbursement of Medicines, and then (since 2013) as what we call ‘reimbursement procedures coordinator’ for the Directorate Pharmaceutical Policy, which means the job is the coordination of the team of the department within the directorate that is responsible for all decision processes (reimbursement of medicines, nutrition, active ingredients, managed entry agreements,..).

Mondher Toumi

Professor Department of Public Health Research Unit

Aix Marseille University

About Mondher

Professor Mondher Toumi is M.D. by training, M.Sc. in Biostatistics, and in Biological Sciences (option pharmacology) and Ph.D. in Economic Sciences. Mondher Toumi is Professor of Public Health at Aix-Marseille University.

After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraces a carrier in the pharmaceutical industry for 13 years.

Mondher Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence.

In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making.

In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD)  an international course already followed by about 500 students. Additionally, he recently created the Market Access Society to promote research and scientific activities around market access, public health and health economic assessment. Since 2009, he also chairs the Annual Market Access Day, a purely academic event. He is editor in Chief of the Journal of Market Access and  Health Policy (JMAHP).

Since September 2014, he joined the research unit EA3279 of the public health department, at Aix-Marseille University (France) as full Professor. Mondher Toumi is also visiting Professor at Beijing University (Third Hospital).

He is a recognized expert in health economics and an authority on market access and risk management. He has more than 200 scientific publications and oral communications, and has contributed to several books. He authored a reference book on Market Access.

 

Luca Morreale

Senior Manager Life Sciences

HighPoint Solutions

Luca is a Senior Manager supporting the European Life Sciences team based out of Geneva, Switzerland assisting clients from Big Pharma, Med Device to Mid and Emerging Pharma as relates to Pricing, Contracting and Tendering Strategy, Operations, and Technology.
• Project Manager in the areas of Commercial Excellence, Pricing, Contracting and Tendering
• SME involved in multiple implementations of Tendering, Contracting, GPM, CRM, Business Intelligence as well as territory alignment tools.
• Business analysis, quality assurance and project management for a range of technology platform ranging from Salesforce, Veeva Vault to SharePoint or Model N Flex.
• Led and published the first major industry benchmarking study on Tendering within Life Sciences.

Paolo Correale

Director, Leader of Tefen Life Sciences Pricing Practice

Tefen Management Consulting

Paolo is a Director at Tefen Europe and the Leader of Tefen’s Life Sciences pricing practice. He has been working as a consultant in Life Sciences and Healthcare for more than eight years, ranging across most functional areas. Over the past five years, Paolo has focused on designing and implementing Pricing, Market Access and Healthcare Partnership solutions for leading MedTech and Pharma players, at both global and local level.

In particular, he supported several multinationals in launching processes, organization and technology to manage all aspects of Pricing, from strategy to execution. His current interest is pioneering innovative pricing models and integrated product-service solutions across the care continuum, facilitating partnerships among Life Sciences companies, Healthcare providers and payers.

 

Antonio Pregueiro

VP Life Sciences Europe

HighPoint Solutions

António is a Vice President of Life Sciences and Commercial Excellence solution lead in Europe. António’s experience spans both biotech and pharma, having worked in strategic marketing, commercial operations and analytics.

Most recently António was the head of a Gastroenterology business unit at Takeda, launching the IBD biologic Entyvio and before that was the head of the Business Operations and Implementation group for Europe and Canada. He received a double honors BSc in Genetics and Biochemistry from the University of Sheffield in the UK and a PhD in Genetics from Dartmouth in the US.

Ben Desmet

Senior Manager

Monitor Deloitte Belgium

Ben is Senior Manager at Monitor Deloitte and has 10 years of experience with supporting clients in their business and commercial transformation journey. Ben is member of the EMEA MedTech Center of Excellence with profound knowledge in both price setting and execution.

TESTIMONIALS

Fresenius-Kabi SwissBioSim

Sue Caleo-Naeyaert, Global Head Pricing, Market Access and Policy Biosimilars at Fresenius-Kabi SwissBioSim

“This is a great conference which covers most pricing topics with a decent amount of detail. Anyone can benefit from this conference no matter how experienced”

Ian Tidswell

Ian Tidswell, Founder and Lead Consultant at een Consulting GmbH

The EPP Life Sciences Pricing Forum is a unique event for learning about the latest pricing challenges and techniques to address them, due to the deep experiences and skills of the participants and speakers

BTG

Giuseppe Monita , Senior Manager, Customer Services Contracts & Tendering EMEA at BTG

“Exciting & energetic meeting where it is possible to learn, share & discuss best practices and new ideas on hot topics regarding pricing & tendering” 

Cogentia Healthcare Consulting

David Alderson, Director at Cogentia Healthcare Consulting

“A good event for catching up, great networking and opportunity to share current thinking and best practice” 

Bayer

Henderson Azevedo, Global Pricing Oncology at Bayer

“A highly recommended forum for pricing professionals”

Tefen Management Consulting

Chiara Garavaglia, Partner, Global Leader of Tefen Life Sciences Centre of Excellence & Innovation at Tefen Management Consulting

“In my experience, EEP is the only existing opportunity to discuss at 360 degrees about Pricing, involving both pharmaceutical and med tech stakeholders”

Sue Caleo-Naeyaert

Sue Caleo-Naeyaert , Global Head Pricing, Market Access and Policy Biosimilars at Fresenius-Kabi SwissBioSim

“This is a great conference which covers most pricing topics with a decent amount of detail.   Anyone can benefit from this conference no matter how experienced”

 

Henderson Azevedo

Henderson Azevedo, Global Pricing Oncology at Bayer

“A highly recommended forum for pricing professionals”

Alan Crowther

Alan Crowther, President, Global Markets at Alliance Life Sciences Consulting Group

“The 7th EPP Life Sciences Pricing Forum was the 3rd in a row that Alliance Life Sciences attended.  This year’s conference was the best yet in content. Participants come prepared to learn, share and together they helped shape the trends in our industry. The forum on the shores of Lake Geneva at the foot of the Alps is also the best locale you can imagine for a thought-provoking, content-rich conference. What a great atmosphere!”

Chiara Garavaglia

Chiara Garavaglia, Partner, Global Leader at Tefen Management Consulting

“In my experience, EEP is the only existing opportunity to discuss at 360 degrees about Pricing, involving both pharmaceutical and med tech stakeholders”

BD

, at BD

Baxter Healthcare

, at

AstraZeneca

, at

Aliaxis

, at

Fresenius

, at

GSK

, at

Merck

, at

Novo Nordisk

, at

Pfizer

, at

Meet pricing decision makers from:

VENUE

Grand Hotel Suisse Majestic – 4*deluxe

This majestic hotel was originally built during the Belle Epoque in 1870 and entirely renovated in 2010. The hotel is just on the lakefront and so you get a phenomenal view of the lake, the promenade, the gardens and of course the snow capped mountains.   Take a look at this splendid hotel !

Please note that we have a limited number of rooms at preferred rates at our disposal : contact Britt Dejager on britt.dejager@pricingplatform.eu to book now !

Avenue des Alpes 45, 1820 Montreux, Zwitserland- +41 21 966 33 33 – hotel website

The easiest way to get to Montreux is to take the train from Geneva Airport direct to Montreux (CHF 35.-/ 2nd class and CHF 62.-/ 1st class)
There is a direct train every 20 minutes (http://www.sbb.ch/en/timetable.html ) – the hotel is straight across the train station.
A taxi will be about CHF 350.-

Photo Grand Hotel Suisse Majestic

Snow capped mountains…

Grand Hotel Suisse Majestic5

…with a great view to the lake…

Grand Hotel Suisse Majestic3

…all comfort in the Belle Epoque…

P1180175

Share, learn and discuss

Grand Hotel Suisse Majestic4

…in an inspiring environment.

P1180607

Perfect work-pleasure combination!

CONTENT

Biosimilar pricing in Europe

When a biosimilar enters the market, the reference drug tends to drop in price in the face of competition, whether through internal or external reference pricing or health technology assesment. 

How to eat the value based procurement elephant ?

Procurement in the health care sector is clearly moving towards procurement of “Value”. In this context, it needs no saying Value-based Procurement will be high on the agenda of both health care providers and suppliers for at least the next few years.

How advanced analytics can help spot price optimization opportunities for a large portfolio of products across different markets

How advanced analytics can help spot price optimization opportunities for a large portfolio of products across different markets

by Halima Benghabrit, Global Pricing Director, Sanofi

Alternative pricing models for the future – Analysis of alternative pricing models such as pay for performance, risk sharing and subscriptions

Alternative pricing models for the future – Analysis of alternative pricing models such as pay for performance, risk sharing and subscriptions

by Finn Ziegler, Director, Global Patient Access, LEO Pharma

New types of contracts to obtain a fair reimbursement of your products

New types of contracts to obtain a fair reimbursement of your products

by Youssef Mamour – CPM, EMEA Pricing Director, Getinge

Download your content here !

We hope you enjoy the content.

EPP PARTNERSHIPS

For more info please contact Britt.dejager@pricingplatform.eu

MEDIA PARTNERS

REGISTRATION

. EPP Members benefit from our preferred membership rates – contact Britt Dejager
. Not yet a member ? Discover all EPP member benefits here 
• Once a registration is completed, tickets are transferable but never refundable. This applies to payments after invoice as well.

FULL CONFERENCE

1995
3-4-5 OCT
Access to workshops
Access to 2 forum days
Access to evening event Oct 4th
PDF presentations after event

BUY 2 GET 1 FREE

3990
3-4-5 OCT
Access to workshops
Access to 2 forum days
Access to evening event Oct 4th
PDF presentations after event

FORUM PASS ONLY

1695
4-5 OCT
 
Access to 2 forum days
Access to evening event Oct 4th
PDF presentations after event

BUY 2 GET 1 FREE

3390
4-5 OCT
 
Access to 2 forum days
Access to evening event Oct 4th
PDF presentations after event

WORKSHOPS ONLY

645
3 OCT
 
Access to workshops
PDF workshop presentations
 

Group discounts are available of > 3 people
Inquire

EXPERT FORUM PASS

2995
4-5 OCT
Access to the 2 forum days
Access to evening event
PDF presentations after event

GROUP RATES

on demand
Group discounts of > 2 people